mutLBSgeneDB |
Gene summary for QPCT |
Gene summary |
Basic gene Info. | Gene symbol | QPCT |
Gene name | glutaminyl-peptide cyclotransferase | |
Synonyms | GCT|QC|sQC | |
Cytomap | UCSC genome browser: 2p22.2 | |
Type of gene | protein-coding | |
RefGenes | NM_012413.3, | |
Description | ECglutaminyl cyclaseglutaminyl-tRNA cyclotransferaseglutamyl cyclase | |
Modification date | 20141207 | |
dbXrefs | MIM : 607065 | |
HGNC : HGNC | ||
Ensembl : ENSG00000115828 | ||
HPRD : 06140 | ||
Vega : OTTHUMG00000100963 | ||
Protein | UniProt: Q16769 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_QPCT | |
BioGPS: 25797 | ||
Pathway | NCI Pathway Interaction Database: QPCT | |
KEGG: QPCT | ||
REACTOME: QPCT | ||
Pathway Commons: QPCT | ||
Context | iHOP: QPCT | |
ligand binding site mutation search in PubMed: QPCT | ||
UCL Cancer Institute: QPCT | ||
Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0017186 | peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferase | 21288892 |
Top |
Ligand binding site mutations for QPCT |
Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.) : non-synonymous mutation on LBS, Circle size denotes number of samples. |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | I321,S323 | P322S | COAD | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for QPCT |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | S323 | P322S | -1.2362622 | I321 | P322S | -1.2362622 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for QPCT from PDB |
Top |
Differential gene expression and gene-gene network for QPCT |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for QPCT |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
umls:C0025202 | Melanoma | 2 | Biomarker |
umls:C0162820 | Dermatitis, Allergic Contact | 1 | Biomarker |
umls:C0023434 | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | Biomarker |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for QPCT |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Gene-centered drug-gene interaction network |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Experimental | DB04581 | 1-benzylimidazole | Small molecule | |
Experimental | DB04622 | N-ACETYLHISTAMINE | Small molecule | |
Experimental | DB04636 | Glutamine t-butyl ester | Small molecule |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of QPCT go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | BGT | L-GLUTAMINE T-BUTYL ESTER HYDROCHLORIDE | 2afu | A | I321 | NVI | 1-VINYLIMIDAZOLE | 2afz | A | I321 | NVI | 1-VINYLIMIDAZOLE | 2afz | B | I321 | PBD | 1-(3,4-DIMETHOXYPHENYL)-3-[3-(1H-IMIDAZOL-1-YL)PROPYL]THIOUREA | 3pbb | A | S323 | PBD | 1-(3,4-DIMETHOXYPHENYL)-3-[3-(1H-IMIDAZOL-1-YL)PROPYL]THIOUREA | 3pbb | B | S323 |
Top |
Conservation information for LBS of QPCT |
Multiple alignments for Q16769 in multiple species |
LBS | AA sequence | # species | Species | D159 | FVGATDSAVPC | 3 | Homo sapiens, Mus musculus, Bos taurus | D248 | LLVLLDLIGAP | 2 | Homo sapiens, Bos taurus | D248 | LLVLLDLIGAA | 1 | Mus musculus | D305 | GGVIQDDHIPF | 2 | Homo sapiens, Bos taurus | D305 | GNIIQDDHIPF | 1 | Mus musculus | E201 | IFFDGEEAFLH | 1 | Homo sapiens | E201 | IFFDGEEAFHH | 1 | Mus musculus | E201 | IFFDGEEAFHL | 1 | Bos taurus | E202 | FFDGEEAFLHW | 1 | Homo sapiens | E202 | FFDGEEAFHHW | 1 | Mus musculus | E202 | FFDGEEAFHLW | 1 | Bos taurus | F325 | LIPSPFPEVWH | 1 | Homo sapiens | F325 | LIASPFPEVWH | 1 | Mus musculus | F325 | LISSPFPEVWH | 1 | Bos taurus | H330 | FPEVWHTMDDN | 3 | Homo sapiens, Mus musculus, Bos taurus | I303 | SYGGVIQDDHI | 1 | Homo sapiens | I303 | GYGNIIQDDHI | 1 | Mus musculus | I303 | GYGGVIQDDHI | 1 | Bos taurus | I321 | PVLHLIPSPFP | 1 | Homo sapiens | I321 | PVLHLIASPFP | 1 | Mus musculus | I321 | PVLHLISSPFP | 1 | Bos taurus | L213 | SPQDSLYGSRH | 3 | Homo sapiens, Mus musculus, Bos taurus | L249 | LVLLDLIGAPN | 1 | Homo sapiens | L249 | LVLLDLIGAAN | 1 | Mus musculus | L249 | LVLLDLIGAPF | 1 | Bos taurus | Q304 | YGGVIQDDHIP | 2 | Homo sapiens, Bos taurus | Q304 | YGNIIQDDHIP | 1 | Mus musculus | S323 | LHLIPSPFPEV | 1 | Homo sapiens | S323 | LHLIASPFPEV | 1 | Mus musculus | S323 | LHLISSPFPEV | 1 | Bos taurus | V302 | YSYGGVIQDDH | 1 | Homo sapiens | V302 | FGYGNIIQDDH | 1 | Mus musculus | V302 | YGYGGVIQDDH | 1 | Bos taurus | W207 | EAFLHWSPQDS | 1 | Homo sapiens | W207 | EAFHHWSPQDS | 1 | Mus musculus | W207 | EAFHLWSPQDS | 1 | Bos taurus | W329 | PFPEVWHTMDD | 3 | Homo sapiens, Mus musculus, Bos taurus | Y299 | FQNYSYGGVIQ | 1 | Homo sapiens | Y299 | FQNFGYGNIIQ | 1 | Mus musculus | Y299 | FRNYGYGGVIQ | 1 | Bos taurus |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |